Influence of KDR Genetic Variation on the Effectiveness and Safety of Bevacizumab in the First-Line Treatment for Patients with Advanced Colorectal Cancer

OBJECTIVE: Bevacizumab is usually considered a first-line anti-tumor therapy, which inhibits tumor growth by downregulating the vascular endothelial growth factor (VEGF) that further silences the activity of the kinase insert region receptor (KDR) gene. In the current study, we investigated the trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fei, Liu, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208669/
https://www.ncbi.nlm.nih.gov/pubmed/35734201
http://dx.doi.org/10.2147/IJGM.S362366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208669/
https://www.ncbi.nlm.nih.gov/pubmed/35734201
http://dx.doi.org/10.2147/IJGM.S362366

Ejemplares similares